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CLINICAL REPORT Guidance for the Clinician in Rendering Pediatric Care
Diagnosis and Management of Infantile
Hemangioma: Executive Summary
David H. Darrow, MD, DDS, Arin K. Greene, MD, Anthony J. Mancini, MD, Amy J. Nopper, MD, the SECTION ON DERMATOLOGY,
SECTION ON OTOLARYNGOLOGY–HEAD & NECK SURGERY, AND SECTION ON PLASTIC SURGERY
INTRODUCTION
Infantile hemangiomas (IHs) are the most common tumors of childhood. Unlike
other tumors, they have the capacity to involute after proliferation, often
leading primary care providers to assume they will resolve without
intervention or consequence. However, a subset of IHs may be associated with
complications, resulting in pain, functional impairment, or permanent
disﬁgurement. As a result, the primary care provider is often called on to decide
which lesions should be referred for early consultation with a specialist.
This document provides a summary of the guidance contained in the
clinical report “Diagnosis and Management of Infantile Hemangioma,”
published concurrently in the online version of Pediatrics (Pediatrics.
2015;136[4]:e1060–e1104, available at: www.pediatrics.org/content/
136/4/e1060.full). The report is uniquely based on input from the many
specialties involved in the treatment of IH. Its purpose is to update the
pediatric community about recent discoveries in IH pathogenesis, clinical
associations, and treatment and to provide a knowledge base and
framework for clinical decision-making in the management of IH.
NOMENCLATURE
• Infantile hemangiomas (IHs) are vascular neoplasms characterized by
abnormal proliferation of endothelial cells and aberrant blood vessel
architecture. In contrast, vascular malformations are structural anoma-
lies and inborn errors of vascular morphogenesis. The latter include
capillary malformations (port wine stains), venous malformations,
lymphatic malformations (formerly known as lymphangiomas or cystic
hygromas), and arteriovenous malformations.
• Congenital hemangiomas are biologically and behaviorally distinct from
IHs. They are fully grown at birth and present as 2 varieties: rapidly
involuting (RICH) and noninvoluting (NICH).
• Pyogenic granuloma, or lobular capillary hemangioma, is a reactive
proliferative vascular lesion. Although classiﬁed with the vascular
neoplasms and often misdiagnosed as IH, pyogenic granuloma is distinct
in its clinical appearance and behavior.
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• Lesions diagnosed as “cavernous
hemangiomas” are usually, in fact,
deep IHs or venous malformations.
• Kasabach–Merritt phenomenon (a
consumptive coagulopathy) is not
associated with IH but rather with
other vascular neoplasms (kaposi-
form hemangioendothelioma and
tufted angioma).
EPIDEMIOLOGY
• The incidence of IH is estimated at
approximately 5% of infants, and
the female/male ratio ranges from
1.4:1 to 3:1.
• IH risk factors include white race,
prematurity, low birth weight, ad-
vanced maternal age, multiple gesta-
tion pregnancy, placenta previa, and
preeclampsia. Other risk factors may
include in utero diagnostic proce-
dures (chorionic villus sampling and
amniocentesis), use of fertility drugs
or erythropoietin, breech pre-
sentation, and being ﬁrst born.
PATHOGENESIS AND HISTOPATHOLOGY
• The pathogenesis of IH remains to
be clearly elucidated. Both intrinsic
factors (such as angiogenic and
vasculogenic factors) and extrinsic
factors (including tissue hypoxia
and developmental ﬁeld dis-
turbances) probably contribute to
development of IH.
• Endothelial progenitor cells may
develop into IH from clonal expan-
sion, resulting in vasculogenesis;
alternatively, fetal progenitor cells
arising from disruption of the pla-
centa during gestation or birth may
give rise to these tumors.
• A unifying theory suggests that IH
results from aberrant proliferation
and differentiation of a pluripotent
progenitor cell, which migrates to
locations in which growth of
placenta-like tissue is favorable.
• Proliferative IHs histologically re-
veal well-deﬁned masses of capil-
laries lined by plump endothelial
cells, arranged in lobules, often
with enlarged draining veins. In-
voluting IHs reveal ﬁbrofatty
stroma, residual “ghost” vessels,
mast cells, and apoptotic bodies.
• Immunohistochemical staining of
IH is positive for glucose trans-
porter 1 (GLUT1), CD31, CD34,
factor VIII–related antigen, and
others; GLUT1 is the most useful
and widely used marker for the
diagnosis of IH.
CLINICAL PRESENTATION
• IHs usually appear before 4 weeks
of age and complete most of their
growth by 5 months of age, al-
though the proliferative phase may
continue up to 12 months of age.
Deep IHs tend to appear later and
grow somewhat longer. The in-
volution phase usually begins be-
tween 6 and 12 months of age, and
the majority of regression occurs
before 4 years of age. As IHs in-
volute, they ﬂatten and shrink, with
fading of their color.
• Up to 70% of IHs leave behind re-
sidual skin changes, including tel-
angiectasia, ﬁbrofatty tissue,
redundant skin, atrophy, dyspig-
mentation, and scar (especially in
lesions with history of past
ulceration).
• Premonitory ﬁndings in early IH
include localized blanching of skin
and macular telangiectatic
erythema.
• During the proliferative phase, IHs
may be classiﬁed based on their
depth, as follows (Fig 1):
• Superﬁcial IH: Surface appears
red, and there is little or no dis-
cernible subcutaneous
component.
• Deep IH: Surface appears blue or
ﬂesh-colored, and the tumor
resides deep below the skin
surface.
• Combined IH: both superﬁcial
and deep components.
• Abortive (arrested growth, mini-
mal growth, nascent) IH (Fig 2)
presents as a telangiectatic patch
that does not uniformly
proliferate.
• IHs may also be classiﬁed accord-
ing to their anatomic conﬁguration:
• Localized (focal) IH: discrete
lesions, arise from single focal
point
• Segmental IH (Fig 3): larger
lesions, usually plaque-like, cov-
ering regions probably de-
termined by neuroectodermal
placodes
• Indeterminate IH: cannot de-
ﬁnitively be categorized as lo-
calized or segmental
• Multifocal IH: focal lesions oc-
curring at more than 1 anatomic
site; may be a marker for hepatic
IH when 5 or more cutaneous
lesions are present
• Segmental IH may be associated
with extracutaneous
manifestations.
• A small subset of children with IH
present with congenital anomalies
recognized as clinical associations.
These include:
• PHACE, which is a congenital
vasculopathy with features of
Posterior fossa defects, Heman-
giomas, cerebrovascular Arterial
anomalies, Cardiovascular
anomalies including Coarctation
of the aorta, and Eye anomalies.
In PHACE, the IH is large and
segmental, characteristically lo-
cated on the face, scalp, or neck.
• LUMBAR, which refers to Lower
body IH and other cutaneous
defects, Urogenital anomalies
and Ulceration, Myelopathy, Bony
deformities, Anorectal malfor-
mations, Arterial anomalies, and
Renal anomalies. The associated
IHs are usually segmental lum-
bosacral or anogenital lesions.
LUMBAR, also described under
the acronyms “SACRAL” and
“PELVIS,” may be thought of
as the “lower half of the body”
variant of PHACE.
PEDIATRICS Volume 136, number 4, October 2015 787
by guest on February 7, 2017Downloaded from 
COMPLICATIONS
• A minority of IH (up to 24% re-
ferred to pediatric dermatologists)
may develop function-threatening
or life-threatening complications,
including:
• Ulceration: most common IH
complication, occurring in 16%
of patients in 1 large series; risk
factors include larger lesions,
segmental IH, and distribution in
the head, neck, perioral, and
perineal or perianal locations
• Bleeding
• Visual impairment: associations
include ptosis, amblyopia,
astigmatism
• Feeding impairment: most often
associated with IH on the lips or
in the aerodigestive tract
• Auditory impairment
• Nasal deformities
• Congestive heart failure: may
occur with large IHs, as a result
of arteriovenous shunting
• Airway obstruction: risk of air-
way IH increased with facial IH
in the “beard” distribution
• Hypothyroidism: may be associ-
ated with diffuse hepatic IH;
caused by excess production of
type 3 iodothyronine deiodinase
• Segmental IHs are much more
likely to develop complications
(usually ulceration) than localized
IH.
• Facial IHs are complicated more
frequently than nonfacial IHs.
IMAGING
• Imaging of IH is not usually
necessary.
• Imaging may be necessary when
the diagnosis is uncertain, when
evaluation of extent is necessary,
when the IH is a possible marker of
PHACE or LUMBAR syndrome, or
when response to therapy must be
monitored.
• When imaging of IH is performed,
ultrasound is the preferred mo-
dality for diagnosis, whereas MRI
is better to assess extent of the
lesion.
CLINICAL APPROACH TO IH
• The indications for intervention for
IH include:
• Emergency treatment of poten-
tially life-threatening
complications
• Urgent treatment of existing or
imminent functional impairment,
pain, or bleeding
• Evaluation to identify important
structural anomalies potentially
associated with IH
• Elective treatment to reduce the
likelihood of long-term or per-
manent disﬁgurement
• There is no algorithm to determine
the most appropriate modality and
timing of intervention for a given
IH. Factors affecting this choice
include:
• Age of the patient
• Growth phase of the lesion
• Location and size of the lesion
• Degree of skin involvement
• Severity of complications and
urgency of intervention
• Potential for adverse psychoso-
cial consequences
• Parental preference
• Physician experience
MANAGEMENT OF ULCERATED IH
• Treatment recommendations for
ulcerated IH are based largely on
FIGURE 1
Cutaneous IHs can be classiﬁed based on their depth. A, Superﬁcial IHs are visible only at the skin
surface and may be focal (as shown here) or segmental. B, Deep IHs have no surface involvement. C,
Mixed, or compound, IHs have both superﬁcial and deep components.
FIGURE 2
Abortive IHs are macular, telangiectatic patches
that have failed to fully proliferate.
FIGURE 3
Segmental IH of the face.
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expert opinion; high-quality studies
of interventions and evidence-
based guidelines are lacking.
• Ulcerated IH management is fo-
cused on wound care, pain control,
controlling IH growth, and pre-
vention and treatment of secondary
infection. Vigilant wound care and
use of barrier ointments or dress-
ings, as well as topical antibiotics,
are generally considered ﬁrst-line
therapy for ulcerated IH.
• For ulcerated IH with suboptimal
response to conservative topical
care, additional medical or surgical
interventions may be needed.
There is growing evidence that
propranolol may be effective in
treating severe ulcerated IH. In
addition, pulsed-dye laser may also
be helpful in treating persistent
ulceration. Rarely, surgical in-
tervention may be indicated in re-
calcitrant ulcerations.
MEDICAL THERAPY FOR IH
• Systemic corticosteroids were the
mainstay of therapy from the
1960s until a 2008 report of
serendipitous improvement of IH
in infants treated with b-blocker
therapy (propranolol).
• b-blocker therapy:
• The mechanism of action of pro-
pranolol, a nonselective blocker
of b-adrenergic receptors that
has been used to treat cardiac
disorders, is not fully un-
derstood. Proposed mechanisms
of action include vasoconstric-
tion, inhibition of angiogenesis,
downregulation of matrix metal-
loproteinases and interleukin-6,
regulation of the renin–angio-
tensin system, and inhibition of
nitric oxide production.
• An oral formulation of pro-
pranolol (Hemangeol [Pierre
Fabre, Castres, France]) for
treatment of IH received ap-
proval from the US Food and
Drug Administration in March
2014. A large 2015 randomized
controlled trial of Hemangeol in
treatment of IH showed effec-
tiveness when dosed at 3.4 mg/
kg per day for 6 months.
• Contraindications to propranolol
therapy include cardiogenic
shock, sinus bradycardia, hypo-
tension, heart block greater than
ﬁrst degree, heart failure, asthma
or reactive airway disease, and
known hypersensitivity to the
drug. Special precautions have
been suggested for children with
PHACE syndrome who have
high-risk intracranial vascular
anomalies.
• Recommendations for pre-
treatment assessment and the
optimal setting for therapy initi-
ation continue to evolve and vary
between clinicians. A complete
history and physical examination
with special attention to the
cardiac and pulmonary systems
aids in assessing a child’s candidacy
for propranolol initiation.
Although some clinicians obtain
pretreatment electrocardiogram
or cardiology consultation before
starting propranolol, the value of
such screening in patients with
an unremarkable cardiac history
and examination is uncertain.
• A consensus report recommends
initiation of propranolol therapy in
a clinic setting with cardiovascular
monitoring hourly for 2 hours
after initiation and recommends
repeat monitoring for dosage
increases of .0.5 mg/kg per day
for infants .8 weeks of age. In-
patient initiation of propranolol is
considered for infants ,8 weeks
of age or infants with post-
conceptual age,48 weeks and for
infants with decreased social sup-
port or increased risk factors.
• Recommended administration of
propranolol is 1 to 3.4 mg/kg per
day divided into 2 or 3 doses.
Duration of therapy is usually
until 8 to 12 months of age, or
between 3 and 12 months of
therapy, depending on age of
initiation and clinical response.
Rebound growth after discontin-
uation of therapy is reported in
5% to 25% of patients; therefore,
some clinicians wean pro-
pranolol over a number of weeks
or months.
• Common adverse effects of pro-
pranolol include sleep distur-
bance, cold hands and feet,
diarrhea, and bronchial hyperre-
activity. Rare adverse effects in-
clude bradycardia and
hypotension, which are generally
asymptomatic, and severe hypo-
glycemia, which may be associ-
ated with decreased
responsiveness or seizures.
• Precautions that may reduce the
risk of hypoglycemia with pro-
pranolol therapy include admin-
istration of medication after
feeding; holding doses when the
patient is ill with decreased oral
intake, vomiting, or diarrhea; and
avoiding prolonged intervals of
longer than 6 hours between
feedings.
• A number of case reports and
case series have reported suc-
cessful use of topical timolol, a b-
blocker used to treat glaucoma,
in the treatment of un-
complicated superﬁcial IH. Ti-
molol 0.5% gel-forming solution
has less systemic absorption
than timolol in solution.
• Corticosteroid therapy:
• For patients with contra-
indications or inadequate re-
sponse to propranolol therapy,
corticosteroids may be an effec-
tive treatment alternative. Most
studies support dosing with oral
prednisolone or prednisone at 2
to 3 mg/kg per day given in
a single morning dose. Several
months of therapy is generally
necessary; treatment is more
likely to be successful when ini-
tiated during IH proliferation.
• Long-term corticosteroid therapy
may be associated with many
adverse effects, including irrita-
bility, sleep disturbance, gastric
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irritation, hypertension, immu-
nosuppression, hypothal-
amic–pituitary–adrenal axis
suppression, linear growth de-
celeration, and cushingoid facies.
These adverse effects are more
frequently seen with higher
doses and prolonged therapy and
tend to be reversible. Periodic
monitoring for potential toxicity,
especially blood pressure eleva-
tion and decreased rate of
growth, is recommended.
• Intralesional steroid injections
are often effective in treating
small, bulky, well-localized IH
lesions. However, although ad-
verse systemic effects have been
reported rarely, intralesional
steroids may be systemically
absorbed, especially when given
in larger doses or multiple
injections, and optimal dosing
and safety proﬁle are not well
studied. As a result, this modality
is no longer considered ﬁrst-line
therapy for most IHs. High-
potency topical steroids have
been reported as effective in the
treatment of small superﬁcial IH,
although their use is largely be-
ing replaced by treatment with
topical b-blockers.
• Other medical therapies:
• Medications other than b-block-
ers and corticosteroids may have
efﬁcacy in treating IH, but their
utility is limited by their safety
proﬁle. Interferon-a appeared to
be a promising treatment option
in the 1980s and early 1990s,
but studies showing signiﬁcant
neurotoxicity have generally
precluded this treatment modal-
ity for IH.
LASER TREATMENT OF IH
• Laser treatment of IH may be use-
ful in treating early non-
proliferating superﬁcial lesions,
salvaging critical skin, controlling
ulceration, and treating persisting
postinvolution telangiectasia. Laser
therapy may also be used as
a component of multimodal
therapy.
• The pulsed-dye laser is used most
commonly, because its light is
preferentially absorbed by
hemoglobin.
• Some studies suggest that the use
of the pulsed-dye laser on pro-
liferating and segmental IHs may
lead to ulceration. Atrophic scar-
ring and hypopigmentation are also
potential complications of laser use
in IH.
SURGICAL THERAPY FOR IH
• Resection of a proliferating IH
generally is not recommended, be-
cause younger patients are at
greater risk of anesthetic morbidity,
blood loss, and iatrogenic injury
than those who undergo operative
intervention later in childhood.
Indications for excising a hemangi-
oma during infancy include failure
of other therapy for a critical IH,
a focal lesion in a favorable loca-
tion, or elective surgery leaving
a scar that would be the same if the
lesion were removed after
involution.
• Delaying surgery until after infancy
allows the lesion time to involute,
becoming smaller and less vascular.
Consequently, the procedure is
safer, and often the patient has
a shorter scar and a higher likeli-
hood of a favorable outcome.
However, most IHs do not improve
signiﬁcantly beyond 4 years of age,
and surgery by this age corrects the
deformity before self-esteem and
long-term memory are well
established.
• Because hemangiomas usually ex-
pand the skin, after they are re-
moved the wound usually can be
reconstructed by linear closure.
Skin grafts and local ﬂaps are rarely
needed.
• Because IH is benign, the entire
lesion does not need to be extir-
pated. The goal is to improve the
appearance of the child, and
subtotal excision often is per-
formed intentionally.
• For circular lesions located on the
face, the length of the scar can be
minimized by circular excision and
purse-string closure. This pro-
cedure also minimizes distortion of
surrounding structures and may
require a second stage to convert
a circular scar into a line.
IHs WITH SPECIAL ANATOMIC
CONCERNS
• IHs involving the eyelids can de-
form the cornea and obstruct the
visual axis, causing astigmatism,
strabismus, or amblyopia. Early
evaluation by a pediatric ophthal-
mologist and early intervention
may reduce the risk of complica-
tions and sequelae.
• Propranolol has largely supplanted
intralesional steroid injection for
treating problematic IHs of the
upper eyelid because the risk of
blindness from embolization of the
retinal artery. However, intrale-
sional steroids are an alternative
for refractory lesions. Topical
b-blockers may be useful for in-
traocular IHs.
• IHs of the airway may occur in
isolation, but patients with large
cutaneous lesions involving the
lower face and neck (the so-called
“beard” distribution) are at greater
risk. Most lesions are subglottic,
and patients so affected can have
biphasic stridor and barky cough
that are often mistaken for croup.
Operative endoscopy is generally
necessary to identify the lesions
and assess their extent. Symptom-
atic lesions are generally treated
with propranolol, but patients who
do not respond rapidly may be
candidates for dilation, intrale-
sional corticosteroid injection, or
partial resection. Open resection
has become less commonly in-
dicated since introduction of pro-
pranolol therapy for IH.
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• Early management of nasal tip IH
using some combination of phar-
macotherapy and laser reduces the
likelihood of long-term deformity
from skin expansion and atrophy
and of injury to the underlying
cartilage. Reconstruction of in-
voluted nasal tip IHs is often nec-
essary even with aggressive early
intervention and includes excision
of the lesion, reconstruction of the
cartilaginous framework, and exci-
sion and redraping of the skin.
• IHs involving the lips and peri-
neum, especially segmental lesions,
have a higher risk of ulceration;
early pharmacotherapy may be ef-
fective in avoiding this complica-
tion. Reduction of friction on
perineal IHs using topical lubrica-
tion with or without a barrier
dressing may help prevent
ulceration.
• IHs located within the vermilion
area of the lip can be removed with
a transverse mucosal incision, al-
though some deep lesions are
best approached through the
vermilion–cutaneous border. Bulkier
lesions that cause lengthening of
the lip and those that cross the
vermilion–cutaneous border are best
addressed with a wedge excision.
Eversion of the lower lip can be
corrected by excision of a mucosal
strip, and correction of inversion
may require a lyophilized dermal
implant or dermal graft.
• The liver is the most common lo-
cation of visceral hemangiomas:
• Infants with $5 cutaneous
hemangiomas are at greater risk
of hepatic lesions and are candi-
dates for screening by
ultrasonography.
• Liver hemangiomas can be focal,
multifocal, or diffuse. Focal
lesions are actually RICHs that
are fully grown at birth and
rapidly involute over the ﬁrst
year of life. Multifocal and diffuse
lesions are true infantile
hemangiomas and often coexist
with cutaneous lesions. Symp-
tomatic multifocal and diffuse
lesions can be treated with sys-
temic pharmacotherapy.
• Infants with signiﬁcant multifo-
cal or diffuse hemangiomas
should undergo thyroid hormone
screening because the tumor can
deactivate thyroid hormone.
Hormone replacement may be
necessary.
• Diffuse lesions may present with
hepatomegaly and cause abdom-
inal compartment syndrome.
CONCLUSIONS
Although many IHs can be observed
without treatment, others will clearly
beneﬁt from medical or surgical
intervention. When complications are
likely or the threshold for
intervention is uncertain, referral to
an experienced specialist or
a multidisciplinary vascular anomaly
center may be advantageous. It is
important for providers of pediatric
care to keep abreast of advances in IH
management as continued research
leads to pathogenesis-directed
therapeutic options and as the types
of intervention and their use evolve.
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